Back to all studies
WithdrawnNCT05974527

Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department

This study has public registry information. It focuses on schizophrenia and currently lists study information in Global.

SchizophreniaOtherOver 18 Years
In plain English

Key information made simple

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care. For people living with Schizophrenia, being understood earlier and more clearly can shape the whole care journey. If the findings are useful, they could help shape larger studies and better designed support in the future. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record does not clearly spell out the visit format, but it appears to be coordinated directly by the research team. Participation appears to involve using a digital tool or support program and giving feedback through check-ins or assessments. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include active substance or alcohol problems that could affect the results and pregnancy or breastfeeding. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT05974527. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may help clarify how this condition is measured or understood.

It requires regular visits and structured follow-up.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Brigham and Women's Hospital
Sponsor type
Hospital / academic medical center
Main activity
digital app or tool
Time commitment
long follow-up or multiple visits
Study phase
Not available
Enrollment
Not available
Recruitment status
Withdrawn
Source
Official registry link
FAQ

Questions about this study

What is Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department?

This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Brigham and Women's Hospital. Based on the sponsor name or official registry information, it appears to be a hospital or academic medical center. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve digital app or tool, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Pilot Study 1: Efficacy and Safety of Sublingual. — Schizophrenia Clinical Trial | HopeStage